Charlotte's Web Holdings Inc (CWBHF)

[DarthYoda]

Here's a bunch of different stuff...

"AHPA publishes updated hemp lexicon":
August 29, 2022
https://www.nutritionaloutlook.com/view/ahpa-publishes-updated-hemp-lexicon
https://www.ahpa.org/hemp_lexicon

"Hemp-derived THC now consumable as an ice cream in Minnesota":
August 29, 2022
https://kvia.com/news/2022/08/29/hemp-derived-thc-now-consumable-as-an-ice-cream-in-minnesota/

"The Colorado hemp industry fantasy":
August 22, 2022
https://www.coloradopolitics.com/opinion/gabel-the-colorado-hemp-industry-fantasy/article_01af70ca-2028-11ed-a8ea-67a4c15cece4.html

Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional study":
24 August 2022

Abstract
Introduction
An estimated 54 million Americans currently suffer from debilitating arthritis. Patients who have exhausted conservative measures can be subject to chronic pain and resort to symptomatic management with anti-inflammatories, acetaminophen, and opioids. Cannabidiol (CBD) is a non-psychoactive cannabinoid that has shown promise in preclinical studies to reduce inflammation and pain associated with arthritis. The purpose of this study was to explore patient perceived effects of cannabidiol on symptoms of arthritis.

Methods
A novel anonymous questionnaire was created to evaluate perceived efficacy of cannabidiol for the treatment of arthritis. A self-selected convenience sample (N=428) was recruited through online methods including social media accounts and newsletters (The Arthritis Foundation and Savvy Cooperative) between May 5, 2020, and November 5, 2020. Statistical analysis was performed to determine differences between types of arthritis and improvements in quality-of-life symptoms. Furthermore, a regression analysis was performed to identify variables associated with decreasing or discontinuing other medications.

Results
CBD use was associated with improvements in pain (83%), physical function (66%), and sleep quality (66%). Subgroup analysis by diagnosis type (osteoarthritis, rheumatoid, or other autoimmune arthritis) found improvements among groups for physical function (P=0.013), favoring the osteoarthritis group. The overall cohort reported a 44% reduction in pain after CBD use (P<0.001). The osteoarthritis group had a greater percentage reduction (P=0.020) and point reduction (P<0.001) in pain compared to rheumatoid arthritis and other autoimmune arthritis. The majority of respondents reported a reduction or cessation of other medications after CBD use (N=259, 60.5%): reductions in anti-inflammatories (N=129, 31.1%), acetaminophen (N=78, 18.2%), opioids (N=36, 8.6%) and discontinuation of anti-inflammatories (N=76, 17.8%), acetaminophen (N=76, 17.8%), and opioids (N=81, 18.9%).

Conclusion
Clinicians and patients should be aware of the various alternative therapeutic options available to treat their symptoms of arthritis, especially in light of the increased accessibility to cannabidiol products. The present study found associations between CBD use and improvements in patient’s arthritis symptoms and reductions in other medications. Future research should focus on exploring the benefits of CBD use in this patient population with clinical trials.

https://link.springer.com/article/10.1186/s42238-022-00154-9

https://www.charlottesweb.com/arthritis-aches-and-pain-cbd-pain-relief-ointment
https://www.arthritis.org/pain/pain-sponsors

"Methods and formulations for efficacious pain relief by transdermal delivery of cannabidiol":
Mar 2, 2021

Patent History
Patent number: 11147777
Type: Grant
Filed: Mar 2, 2021
Date of Patent: Oct 19, 2021
Assignee: Charlotte's Web, Inc. (Boulder, CO)
Inventors: Perry Antelman (Sharon, MA), Bharat Madhavan (Kingston, RI), Shalom Lampert (Maalot)
Primary Examiner: Theodore R. Howell
Application Number: 17/189,484

https://patents.justia.com/patent/11147777#history

"The potential of cannabinoids in the treatment of lung cancer":
2022-08-25

Abstract
Introduction: Lung cancer is the number-one cause of death due to neoplasms worldwide. The 5-year overall survival rate is only 22%. In advanced stages, the therapeutic options are limited to chemotherapy, radiotherapy, molecularly targeted therapy and immunotherapy. Phytocannabinoids, the components of Cannabis sativa, their synthetic derivatives and endogenous cannabinoids have demonstrated anticancer activity in various common cancers - breast, prostate, colorectal and lung cancers, among others. The aim of this review was to assess the potential value of cannabinoids in the treatment of lung cancer.

State of knowledge: The majority of preclinical studies demonstrates that cannabinoids inhibit lung cancer cell viability both in vitro and in vivo. The main mechanism of anticancer activity is the induction of apoptosis, triggered by activation of CB1, CB2 and TRPV1 receptors or independently via other pathways. Cannabinoids influence the components of the tumour microenvironment - cancer associated fibroblasts, macrophages and lymphokine-activated-killer cells. Cannabinoids alter leukocyte infiltration into anti-cancer proportions, inhibit expression of EGFR and PAI-1 and increase the expression of TIMP-1. As a result they induce cytotoxicity, decrease proliferation, migration and invasive potential of lung cancer cells, suppress angiogenesis and metastasis forming. Patients with advanced lung cancer may also benefit from analgesic, antiemetic and appetite improving properties of cannabinoids.

Summary: Cannabinoids can be a supplementary agent in systemic anticancer therapeutic regimen in the future. The exact mechanisms of action, specific doses in anticancer treatment, routes of administration and interactions with other anticancer drugs has yet to be determined. Thus the clinical studies on cannabinoids in lung cancer should be performed in the future.

https://apcz.umk.pl/JEHS/article/view/39529